Plain-English translation of NCT06839560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment approach for people with advanced breast cancer that has spread to the brain. The treatment combines an immune-boosting medication called Adebrelimab with three chemotherapy pills taken by mouth (vinorelbine, cyclophosphamide, and capecitabine) and targeted radiation therapy to the brain. The study will compare whether giving the radiation therapy right away works better than delaying it.
Brain metastasis—when cancer spreads to the brain—is a serious complication of advanced breast cancer that is difficult to treat. Researchers want to see if combining this medication with chemotherapy and radiation can improve outcomes and help people with this condition live longer.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups. Both groups receive the immune medication as an injection every three weeks and take three chemotherapy pills by mouth on a regular schedule. One group receives brain radiation within the first three weeks, while the other group delays radiation. You will need regular clinic visits for treatment, blood tests to check your health, and MRI scans to see how the cancer is responding. The study involves about 102 participants across multiple cancer centers.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China